Methods of using gelsolin to treat or prevent bacterial sepsis
View Patent ↗Provided are methods of using gelsolin and active fragments thereof to neutralize, treat or prevent the pathogenic effects of lipoteichoic acid (LTA) toxins released from gram-positive bacteria, including massive activation of inflammatory response in a patient and the resulting lethal septic shock. The provided gelsolin binds to and neutralizes LTA from various bacteria, as well as eukaryotic acidic lysolipids adversely associated with bacterial sepsis and inflammation in the patient, with high affinity, thereby decreasing circulating LTA and the eukaryotic markers, and negating the deleterious biological effects of the gram-positive bacterial infection. Consequently, the provided gelsolin replacement therapy offers a method and compositions for the prevention of bacterial sepsis-induced mortality in the patient.
1. A method of reducing risk of septic shock in a patient who is infected with bacteria, and who is at risk of septic shock, the method comprising:
(a) measuring a blood gelsolin concentration of a patient who is infected with bacteria;
(b) determining that the patient is at risk of septic shock if the blood gelsolin concentration of the patient is less than 30% of matched, pre-infection, pre-trauma control subjects, but not at risk of septic shock if the circulating gelsolin concentration of the patient is greater than 30% of matched, pre-infection, pre-trauma control subjects; and
(c) parenterally administering gelsolin to the patient if the patient has been determined to be at risk of septic shock.
2. A method of reducing risk of septic shock in a patient who is infected with gram-positive bacteria, and who is at risk of by gram-positive bacterium-induced sepsis, the method comprising:
(a) measuring a blood gelsolin concentration of a patient who is infected with gram-positive bacteria;
(b) determining that the patient is at risk of gram-positive bacterium-induced sepsis if the blood gelsolin concentration of the patient is less than 30% of matched, pre-infection, pre-trauma control subjects, but not at risk of gram-positive bacterium-induced sepsis if the circulating gelsolin concentration of the patient is greater than 30% of matched, pre-infection, pre-trauma control subjects; and
(c) parenterally administering gelsolin to the patient if the patient has been determined to be at risk of gram-positive bacterium-induced sepsis.
3. The method of claim 1 , wherein the bacterial infection releases endotoxin lipoteichoic acid (LTA).
4. The method of claim 3 , wherein the lipoteichoic acid (LTA) is released from a gram-positive bacterium.
5. The method of claim 4 , wherein the gram-positive bacterium is Streptococcus pneumoniae or Staphylococcus aureus.
6. The method of claim 2 , wherein the gram-positive bacterium is Streptococcus pneumoniae or Staphylococcus aureus.
7. The method of claim 1 , wherein the bacterial infection releases endotoxin lipopolysaccharide (LPS).
8. The method of claim 7 , wherein the lipopolysaccharide (LPS) is released from a gram-negative bacterium.
9. The method of claim 8 , wherein the gram-negative bacterium is Escherichia coli, Salmonella enteriditis or Klebsiella pneumoniae.
10. The method of claim 1 , wherein the gelsolin is administered intravenously, intramuscularly, intraperitoneally, or subcutaneously.
11. The method of claim 2 , wherein the gelsolin is administered intravenously, intramuscularly, intraperitoneally, or subcutaneously.
12. The method of claim 1 further comprising administering to the patient an expression vector containing a nucleic acid which encodes gelsolin.
13. The method of claim 2 further comprising administering to the patient an expression vector containing a nucleic acid which encodes gelsolin.